Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Skin Cancer Regimens



Basal cell Regimens


Published

Name Version Date
SKIN BCC Metastatic - vismodegib1.0.030/09/2021

Melanoma Regimens


Published

Name Version Date
SKIN Melanoma Metastatic - [for brain metastasis] ipilimumab 3mg/kg and nivolumab 1mg/kg1.0.002/08/2024
SKIN Melanoma Metastatic - biNIMEtinib and encorafenib1.0.030/09/2021
SKIN Melanoma Metastatic - cARBOplatin, PACLItaxel, and beVACizumab4.0.013/08/2023
SKIN Melanoma Metastatic - cOBIMEtinib and vemurafenib1.0.030/09/2021
SKIN Melanoma Metastatic - daBRAFEnib and tRAMEtinib2.0.005/07/2022
SKIN Melanoma Metastatic - dacarbazine2.0.013/08/2023
SKIN Melanoma Metastatic - imatinib1.0.030/09/2021
SKIN Melanoma Metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg1.0.030/09/2021
SKIN Melanoma Metastatic - ipilimumab and pembrolizumab1.0.030/09/2021
SKIN Melanoma Metastatic - nivolumab Q2W [flat dosing]1.0.030/09/2021
SKIN Melanoma Metastatic - nivolumab Q2W [weight based dosing]1.0.030/09/2021
SKIN Melanoma Metastatic - nivolumab Q4W [flat dosing]1.0.030/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q3W [flat dosing]1.0.030/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q3W [weight based dosing]1.0.030/09/2021
SKIN Melanoma Metastatic - pembrolizumab Q6W [flat dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - daBRAFEnib and tRAMEtinib2.0.005/07/2022
SKIN Melanoma NON-Metastatic - nivolumab Q2W [flat dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - nivolumab Q2W [weight based dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [flat dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [weight based dosing]1.0.030/09/2021
SKIN Melanoma NON-Metastatic - pembrolizumab Q6W [flat dosing]1.0.030/09/2021